- Used in combination with AI like letrozole as first-line therapy for patients with metastatic, ER-positive breast cancer
- highly selective, oral inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6)
- Major side effects include neutropenia, fatigue, nausea, and alopecia
- administered in a 28 day cycle (21 days on, 1 week of rest for bone marrow recovery)
Posted 09/12/16 02:05:23 PM by Anna Krigel
- Neutropenia -> ANC < 1500 cells/microL (severe neutropenia -> ANC < 500 cells/microL)
- Calculate ANC by taking total WBC count and multiplying by percentage of PMNs and bands
- Initiate empiric antibiotic therapy according to the neutropenic fever guidelines immediately after blood cultures are obtained and before any other investigations are completed
Posted 09/12/16 02:51:52 PM by Anna Krigel
mTOR inhibition in LAM (lymphangioleiomyomatosis)
- sirolimus (Rapamycin) has been shown to slow disease progression in moderate-to-severe pulmonary LAM
- patients with LAM typically have mutations in the tumor suppressor gene encoding tuberin (TSC2), which normally inhibits mTOR activation
- sirolimus inhibits the mTOR complex
- has been associated with amelioration of pulmonary function tests, chylous effusions, and lymphangioleiomyomas
- also being used to treat PEComas
Posted 09/12/16 03:19:48 PM by Anna Krigel
For further reading...
Posted 09/12/16 03:39:59 PM by Anna Krigel
Created by Christopher Kelly
Know a hypochondriac? Get them the best-selling book 'AM I DYING?!: A Complete Guide to Your Symptoms, and What to Do Next'
The information on the website does not constitute official guidelines except where explicitly stated.
It is not meant to replace the advice of a health professional.